MDxHealth stock extends strong August rally after beating Q2 revenue expectations
Published on 08/29/2026 at 12:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
MDxHealth SA (ISIN US55278X1072) stock has delivered a sharp move higher in late August 2026, with shares trading at $0.85 and the company’s market capitalization at $44 million as of August 28, 2026, according to recent market data for its Nasdaq listing (ticker MDXH). Per a same-day markets snapshot, the stock gained 5.3% in that session and is up 85% since August 13, 2026, following the release of its second quarter revenue figures.
Q2 2026 revenue beat underpins the move
The immediate catalyst for the August advance has been MDxHealth’s second quarter 2026 results. Recent reporting on the company’s performance states that second quarter revenue rose 16% year-over-year to $27.2 million in the period ended June 30, 2026, reflecting continued demand for its urologic cancer diagnostic tests. The same report notes that this $27.2 million revenue figure exceeded a widely followed consensus estimate by 5.5%, signaling a clear beat versus expectations and helping explain the sharp positive reaction in the stock.
This quantified comparison - 16% year-over-year revenue growth and a 5.5% revenue beat - matters for investors because it shows that MDxHealth did not simply match, but exceeded what analysts had penciled in for the quarter. In the small-cap diagnostics space, a double signal of accelerating top-line growth and an upside surprise versus consensus can quickly improve sentiment and encourage investors to reassess the company’s longer-term revenue potential. For MDxHealth, this effect has been visible in the share price, with the 85% gain since August 13, 2026 lining up directly with the timing of the Q2 2026 report.
Stock performance and trading context
From a trading perspective, MDxHealth’s move has pushed the shares back toward the upper part of their recent range. One markets overview published August 28, 2026 cites the $0.85 quote and $44 million market cap for the Nasdaq-listed stock, indicating that the session closed firmly positive after the Q2 report. Another market-data page focused on MDxHealth’s Nasdaq quote shows a last price of $0.7561 on August 26, 2026, with a five-day performance of negative 4.15%, a year-to-date change of negative 0.40%, and a 52-week performance of negative 78.82%. This structure suggests that while the August rally has been strong in percentage terms over a short window, the stock remains well below its levels of the prior year.
This combination of numbers - a recent price of $0.7561 on August 26, 2026 and a subsequent move to $0.85 on August 28, 2026 with an 85% gain since mid-August - highlights the volatility typical of smaller health-care names. For traders, the key takeaway is that MDxHealth’s August move has been driven by a fundamental data point (the Q2 2026 revenue beat), but the shares still carry a long-term drawdown of nearly 79% over the past 52 weeks, according to the quoted market portal statistics. That tension between short-term momentum and longer-term weakness often shapes risk-reward thinking in this part of the market.
Fundamentals and guidance context
Within the constraints of the available same-day sources, the most recent fundamental picture that can be treated as current comes from the second quarter of 2026. The reported revenue of $27.2 million for Q2 2026, up 16% year-over-year and 5.5% above consensus, shows that MDxHealth is successfully expanding its commercial footprint and test utilization in urologic oncology. The year-over-year comparison implies that the company’s product lines, which include genomic tests used to stratify prostate cancer risk and assist in biopsy decisions, are finding broader acceptance in clinical practice and among payers.
Although the exact net income or adjusted EBITDA figures for Q2 2026 are not detailed in the same market snapshot, the description of the quarter as one where revenue growth exceeded expectations supports the view that MDxHealth is making progress on the revenue side of its path toward scale. Historically, diagnostics companies require sustained top-line growth to absorb fixed costs associated with laboratory infrastructure, reimbursement operations, and sales teams; a 16% revenue increase in Q2 2026 is a meaningful step in that direction, especially when the company is still trading at a sub-$1 share price on Nasdaq.
The consensus picture also appears constructive. The same coverage that notes the Q2 2026 revenue beat refers to a consensus estimate that was surpassed by 5.5%, implying that analysts tracking MDxHealth had set expectations at a level the company was able to exceed. While no explicit earnings-per-share forecast or forward revenue guidance is cited in the same-day excerpts, the direction of the surprise - upside rather than downside - tends to bolster confidence that MDxHealth’s management team has reasonable visibility on test demand trends and payer behavior in its core markets.
Analyst and investor reaction
The August price move and revenue surprise have also prompted renewed interest among investors. The 85% share-price rise since August 13, 2026, highlighted in the markets newsletter, shows that the Q2 2026 earnings event materially altered the demand for MDXH shares over a short period. For a company with a $44 million market cap at a price of $0.85, this level of re-rating means that incremental buying can have a substantial effect on the share price.
In the health-care diagnostics space, such a reaction often reflects not just the quarter’s numbers, but a reassessment of the medium-term growth trajectory. If MDxHealth can sustain mid-teens or better revenue growth while managing costs, investors may begin to factor in a meaningful trajectory toward break-even or profitability. The Q2 2026 beat, particularly the 16% revenue increase, is therefore more than a one-off data point; it is a potential sign that the company is executing its commercial strategy effectively and that its tests are gaining traction among clinicians focused on prostate and other urologic cancers.
Representative product: urologic cancer diagnostics
MDxHealth’s business model centers on molecular diagnostics designed to improve decision-making in urologic oncology, especially prostate cancer. The company offers genomic tests that help physicians evaluate whether a patient’s prostate cancer is likely to be aggressive, which supports choices between active surveillance and more intensive treatment. These diagnostics are intended to reduce overtreatment in low-risk patients while ensuring that higher-risk cases are identified and managed promptly.
For investors, this product positioning matters because prostate cancer remains one of the most common cancers in men, creating a large potential addressable market for risk-stratification tools that can be integrated into clinical workflows and reimbursement pathways. The revenue growth reported in Q2 2026 suggests that these tests are being adopted more broadly, supporting both clinical outcomes and MDxHealth’s commercial expansion.
Shares on Nasdaq and current trading level
MDxHealth SA’s shares trade on Nasdaq under the ticker MDXH, giving US investors direct access to the company’s equity. According to the markets newsletter filed August 28, 2026, the stock closed that session at $0.85 with a $44 million market cap after rising 5.3%, and the same source highlighted the 85% increase since August 13, 2026. A separate market-data overview for MDXH’s Nasdaq listing pointed to a last price of $0.7561 on August 26, 2026, with a five-day performance of negative 4.15%, year-to-date performance of negative 0.40%, and a 52-week performance of negative 78.82%, underscoring both the recent volatility and the longer-term drawdown.
Read more
More on MDxHealth stock and its recent Q2 2026 revenue performance can be found via the company’s investor communications and same-day markets coverage, which provide deeper detail on segment trends, reimbursement developments, and management’s outlook for the remainder of 2026.
MDxHealth’s cancer test portfolio
MDxHealth’s portfolio of molecular diagnostics is focused on supporting urologists and oncologists in managing prostate and other urologic cancers. The company’s tests use genomic information from patient samples to assess the likelihood that a detected tumor will behave aggressively, helping clinicians decide whether to pursue active surveillance, surgery, radiation, or other treatment options. This clinical decision-support role is central to the company’s value proposition, as it aims to reduce unnecessary biopsies and more invasive interventions in patients whose cancers are less likely to progress quickly.
From a commercial standpoint, the Q2 2026 revenue figures suggest that demand for these tests is growing. With revenue of $27.2 million in the quarter ended June 30, 2026, up 16% versus the prior year period and 5.5% above consensus, MDxHealth is demonstrating that its portfolio can generate sustained revenue growth. If this trajectory continues, the company could gain additional scale, improve margins, and invest further in new test development and market expansion. In the broader diagnostics market, companies that can tie solid clinical evidence to growing revenue streams often attract increasing attention from both specialized health-care investors and generalist funds looking for exposure to precision medicine trends.
Stock level and investor lens
As of August 28, 2026, MDxHealth stock’s closing price of $0.85 on Nasdaq and market capitalization of $44 million frame the company as a small-cap diagnostics name with significant volatility and a meaningful recent recovery from mid-August levels. For investors, the key numerical signals are the 16% revenue growth to $27.2 million in Q2 2026, the 5.5% revenue beat versus consensus in the same period, and the 85% share-price increase since August 13, 2026 highlighted in markets coverage. These figures collectively indicate that the Q2 2026 report has changed sentiment around the stock, even as the longer-term 52-week performance remains deeply negative.
Fact box
Company: MDxHealth SA
ISIN: US55278X1072
Ticker: MDXH
Exchange: Nasdaq
Price (as of August 28, 2026, session close): $0.85 USD
Market cap: $44 million (as of August 28, 2026)
Sector / Industry: Health-care / Diagnostics
